ELP fusion proteins for controlled and sustained release
US10722590B2 · kind B2 · utility
0Cited by
7References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2015 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Nov 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The pharmaceutical formulations comprise a therapeutic agent including an active agent and an amino acid sequence capable of forming a reversible matrix at the body temperature of a subject. The disclosure provides improved pharmacokinetics for peptide and small molecule drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.